← Leaderboards
Luis Manuel Branco
Zalgen Labs, Llc
$8,299,527
Attributed
$8,299,527
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2015–23$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,299,527 · 3
By mechanism
R01$6,295,715 · 1
R44$1,856,094 · 1
R43$147,718 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Africa”
- Wafaa M. El-Sadr · Columbia University Health Sciences$372,070,023
- Myron S Cohen · Family Health International$371,035,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$169,486,689
- Carol Nesel · Westat$157,229,158
- Constance Ann Benson · University Of California, San Diego$156,911,346
- Sten H Vermund · University Of Alabama At Birmingham$130,129,209
Research focus
AfricaLassa VirusNational Institute Of Allergy And Infectious DiseaseReportingBaseMonoclonal AntibodiesAntibodiesVirusLassa FeverViral Hemorrhagic FeversProgramsPreclinical EvaluationClinical ResearchCommercializationAchievementViral AntigensWeaponsDesignReadinessAntiviral AgentsNonhuman PrimateTechnologyGlycoproteinsHuman Monoclonal Antibodies
Grant awards (8)
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,180,007
R01 · FY2023 · AI · contact PI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,192,954
R01 · FY2022 · AI · contact PI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,202,174
R01 · FY2021 · AI · contact PI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,222,182
R01 · FY2020 · AI · contact PI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,498,398
R01 · FY2019 · AI · contact PI
Late-stage development toward commercialization of multilineage point-of-care Lassa fever diagnostics$928,504
R44 · FY2016 · AI · contact PI
Late-stage development toward commercialization of multilineage point-of-care Lassa fever diagnostics$927,590
R44 · FY2015 · AI · contact PI
Evaluation of fully human Pan-Old World Arenavirus monoclonal antibodies as candidate therapeutics for LCMV infection$147,718
R43 · FY2015 · AI · contact PI